Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's expectations and bumping its stock up more than 4% at market open.

Novo Nordisk and Eli Lilly have used submissions to the federal government’s budget process to argue reducing obesity will be ...

Novo Nordisk (NVO) stock and Eli Lilly (LLY) stock higher as Novo (NVO) reports strong Q4 2024 earnings, driven by sales ...

Novo Nordisk shares rose Wednesday after fourth-quarter earnings beat Wall Street's estimates, 2025 forecast came in line with expectations. Novo CEO Lars Fruergaard Jorgensen sees Wegovy supply ...